Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the Basel spinout.

Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the bacteria-based cancer drug developer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UCL's gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

The gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.

GlaxoSmithKline is paying $176m for a 10% stake in the RNA drug developer in connection with a strategic partnership agreement.

Juno Capital has said neither Neil Woodford or Craig Newman have been appointed with the firm, denying earlier reports to the contrary.